

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Prescient Therapeutics Limited
ABN	56 006 569 106

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Paul Hopper
Date of last notice	21 December 2016

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Deborah Anne Coleman (a related party of Mr Hopper) Moreglade Pty Ltd (a controlled entity of Mr Hopper) Kilinwata Investments Pty Ltd (a controlled entity of Mr Hopper)
Date of change	30 June 2018

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

<p>No. of securities held prior to change</p> <p>Paul Edward Alexander Hopper</p> <p>Deborah Anne Coleman (a related party of Mr Hopper)</p> <p>Moreglade Pty Ltd (a controlled entity of Mr Hopper)</p> <p>Kilinwata Investments Pty Ltd (a controlled entity of Mr Hopper)</p>	<p>1,038,137 Fully paid ordinary shares</p> <p>2,216,667 Fully paid ordinary shares</p> <p>2,333,334 Fully paid ordinary shares</p> <p>3,572,778 Fully paid ordinary shares 22,222 Listed Options 247,000 Unlisted options exercisable at \$0.1194 (11.94 cents) per option, expiring on 21 December 2019</p>
<p>Class</p>	<p>Listed Options</p>
<p>Number acquired</p>	<p>-</p>
<p>Number disposed</p>	<p>22,222 Listed Options</p>
<p>Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation</p>	<p>Nil</p>
<p>No. of securities held after change</p> <p>Paul Edward Alexander Hopper</p> <p>Deborah Anne Coleman (a related party of Mr Hopper)</p> <p>Moreglade Pty Ltd (a controlled entity of Mr Hopper)</p> <p>Kilinwata Investments Pty Ltd (a controlled entity of Mr Hopper)</p>	<p>1,038,137 Fully paid ordinary shares</p> <p>2,216,667 Fully paid ordinary shares</p> <p>2,333,334 Fully paid ordinary shares</p> <p>3,572,778 Fully paid ordinary shares 247,000 Unlisted options exercisable at \$0.1194 (11.94 cents) per option, expiring on 21 December 2019</p>
<p>Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>Lapse of Listed Options expiring on 30 June 2018</p>

+ See chapter 19 for defined terms.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺ closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Prescient Therapeutics Limited
ABN	56 006 569 106

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Steven Lee Yatomi-Clarke
Date of last notice	21 December 2016

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	<ol style="list-style-type: none"> 1. Arrow Wealth Ltd <Berbay Family A/C> (a controlled entity of Mr Yatomi-Clarke) 2. Novetera Pty Ltd <SAYC Super Fund A/C> (a controlled entity of Mr Yatomi-Clarke) 3. Alexandra Elizabeth Yatomi-Clarke
Date of change	30 June 2018
No. of securities held prior to change	<ol style="list-style-type: none"> 1. 3,245,000 Fully paid ordinary shares 200,000 Unlisted options 2. 976,912 Fully paid ordinary shares 70,000 Listed Options 3. 172,500 Fully paid ordinary shares
Class	Listed Options

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Number acquired	
Number disposed	70,000 Listed Options
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil
No. of securities held after change	<ol style="list-style-type: none"> 1. 3,245,000 Fully paid ordinary shares 200,000 Unlisted options 2. 976,912 Fully paid ordinary shares 3. 172,500 Fully paid ordinary shares
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Lapse of Listed Option expiring on 30 June 2018

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.